Treating non-ST-segment elevation ACS

References

• Braunwald E. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed Jul 11, 2005
   Google Scholar
• Gluckman TJ, Sachdev M, Schulman SP, et al. A simplified approach to the management of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 293(3): 349–57 [Erratum, JAMA 2005; 293(14): 1728]
   Google Scholar
• Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation 2003; 108(16 Supp1 1): III28–37
   Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685–95
   PubMed Web of Science ®Google Scholar
• Russell RO Jr, Moraski RE, Kouchoukos N, et al. Unstable angina pectoris: National Cooperative Study Group To Compare Surgical and Medical Therapy. II. In-hospital experience and initial follow-up results in patients with one, two and three vessel disease. Am J Cardiol 1978; 42: 839–48
   Google Scholar
• Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris: results of a Veterans Administration Cooperative Study. N Engl J Med 1987; 316(16): 977–84
   Google Scholar
• Cannon CP, Weintraub WS, Demopoulos LA, et al; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344(25): 1879–87
   PubMed Web of Science ®Google Scholar
• Fox KA, Poole-Wilson PA, Henderson RA, et al; Randomized Intervention Trial of Unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of Unstable Angina. Lancet 2002; 360(9335): 743–51
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment (“cooling-off strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003; 290(12): 1593–9
   Google Scholar
• Choudhry NK, Singh JM, Barolet A, et al. How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials. Am J Med 2005, 118(5): 465–74
   Google Scholar
• Stukel TA, Lucas FL, Wennberg DE. Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare patients with acute myocardial infarction. JAMA 2005; 293(11): 1329–37
   Google Scholar
• Rathore SS, Epstein AJ, Volpp KG, et al. Regionalization of care for acute coronary syndromes: more evidence is needed. JAMA 2005; 293(11): 1383–7
   Google Scholar
• Montalescot G, Dabbous OH, Lim MJ, et al; Global Registry of Acute Coronary Events Investigators. Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational Global Registry of Acute Coronary Events. Am J Cardiol 2005; 95(12): 1397–403
   Google Scholar
• de Araujo Goncalves P, Ferreira J, Aguiar C, et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26(9): 865–72
   Google Scholar
• Scirica BM, Cannon CP, Antman EM, et al. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol 2002; 90(3): 303–5
   Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502 [Errata, N Engl J Med 2001; 345(23): 1716 and 2001; 345(20): 1506]
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19): 2411–20 [Erratum, JAMA 2003; 289(8): 987]
   PubMed Web of Science ®Google Scholar
• Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319(17): 1105–11
   PubMed Web of Science ®Google Scholar
• Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990; 336(8719): 827–30
   PubMed Web of Science ®Google Scholar
• Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88(5 Pt 1): 2045–8
   PubMed Web of Science ®Google Scholar
• Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the AT ACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89(1): 81–8
   Google Scholar
• Hold right D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24(1): 39–45
   Google Scholar
• Low-molecular-weight heparin during instability in coronary artery disease. Fragmin During Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347(9001): 561–8
   Google Scholar
• Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 1999; 354(9180): 701–7 [Erratum, Lancet 1999; 354(9188): 1478]
   Google Scholar
• Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low- molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non- Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337(7): 447–52
   PubMed Web of Science ®Google Scholar
• Antman EM, McCabe CH, Gurfinkel EP, et al; TIMI IIB Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) IIB Trial. Circulation 1999; 100: 1593–601
   PubMed Web of Science ®Google Scholar
• Califf RM, Petersen JL, Hasselblad V, et al. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Am Heart J 2005; 149: s91–9
   Google Scholar
• Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial. Lancet 2001; 357(9272): 1915–24
   PubMed Web of Science ®Google Scholar
• Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987; 60(2): 18A–25A
   Web of Science ®Google Scholar
• Hohnloser SH, Meinertz T, Klingenheben T, et al. Usefulness of es-molol in unstable angina pectoris. European Esmolol Study Group. Am J Cardiol 1991; 67(16): 1319–23
   Google Scholar
• Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315(7): 423–9
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711–8
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292(11): 1307–16
   PubMed Web of Science ®Google Scholar
• Zhou Z, Rahme E, Abrahamowicz M, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172(9): 1187–94
   Google Scholar
• ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106: 1883–92
   PubMed Web of Science ®Google Scholar